tiprankstipranks
Trending News
More News >
Advertisement

MVAL - ETF AI Analysis

Compare

Top Page

MVAL

VanEck Morningstar Wide Moat Value ETF (MVAL)

Rating:70Neutral
Price Target:
MVAL (VanEck Morningstar Wide Moat Value ETF) appears to be a solid, quality-focused fund, supported by strong core holdings like Merck and Bristol-Myers Squibb, which bring robust financial performance, attractive valuations, and promising growth pipelines. Additional contributors such as Danaher and Kenvue add to the fund’s appeal through healthy cash flows and strategic initiatives, though names like Boeing and Estée Lauder, with their profitability, leverage, and valuation challenges, likely weigh on the overall rating. The main risk factor is that several sizable holdings face financial or valuation pressures, which could increase volatility if these issues are not resolved.
Positive Factors
Broad Sector Mix in Defensive Areas
The fund spreads its investments across several sectors, with a tilt toward consumer defensive and health care companies that can be more resilient in weaker economies.
Generally Strong Top Holdings
Most of the largest positions, including companies like Constellation Brands, Boeing, and United Parcel, have shown strong year-to-date performance, helping support the ETF’s overall returns.
Positive Recent Performance Trend
The ETF has delivered steady gains over the past month, three months, and year-to-date, indicating positive recent momentum.
Negative Factors
High U.S. Concentration
Almost all of the fund’s assets are invested in U.S. companies, which limits diversification across global markets.
Sector Concentration in a Few Areas
A large share of the portfolio is concentrated in consumer defensive, health care, and industrials, increasing the impact if these sectors face a downturn.
Mixed Performance Among Top Holdings
Some key positions, such as Zimmer Biomet and Campbell Soup, have shown weak year-to-date performance, which can drag on overall returns.

MVAL vs. SPDR S&P 500 ETF (SPY)

MVAL Summary

The VanEck Morningstar Wide Moat Value ETF (MVAL) tracks the Morningstar US Broad Value Wide Moat Focus Index, which focuses on U.S. companies judged to have strong, lasting competitive advantages and to be attractively priced. It holds well-known names like Merck and United Parcel Service (UPS), spread across defensive, health care, industrial, and other sectors. Someone might invest in MVAL to seek long-term growth from high-quality value stocks while staying diversified across many industries. A key risk is that these value stocks can still fall in price and move up and down with the overall stock market.
How much will it cost me?The VanEck Morningstar Wide Moat Value ETF (MVAL) has an expense ratio of 0.49%, which means you’ll pay $4.90 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is actively managed, focusing on selecting companies with strong competitive advantages. Active management typically involves more research and analysis, which can lead to higher costs.
What would affect this ETF?The VanEck Morningstar Wide Moat Value ETF (MVAL) could benefit from long-term growth in sectors like Health Care and Consumer Defensive, which are its largest exposures and tend to perform well during economic uncertainty. However, rising interest rates or economic slowdowns could negatively impact industrial and cyclical sectors, which also make up a significant portion of the ETF's holdings. Regulatory changes or competitive pressures affecting top holdings like Thermo Fisher or Nike may also influence the ETF's performance.

MVAL Top 10 Holdings

MVAL is leaning heavily on U.S. health care and consumer defensive giants, with Merck and Bristol-Myers Squibb doing much of the heavy lifting as their shares keep rising on solid pipelines and steady results. UPS and Boeing add an industrial tilt; UPS has been quietly climbing, while Boeing is more of a roller coaster—recent gains but still weighed down by operational and financial baggage. On the defensive side, Constellation Brands and Campbell Soup are more mixed, with sluggish or choppy trading that keeps them from fully pulling their weight.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Merck & Company5.33%$401.14K$286.28B22.33%
80
Outperform
Bristol-Myers Squibb5.17%$388.74K$122.78B-1.31%
78
Outperform
United Parcel4.81%$361.75K$86.91B-15.84%
72
Outperform
Kenvue, Inc.4.32%$325.25K$35.25B-21.48%
73
Outperform
Constellation Brands4.25%$319.35K$25.40B-21.36%
67
Neutral
Boeing4.17%$313.77K$181.50B49.90%
54
Neutral
Danaher4.00%$300.98K$138.25B-7.81%
75
Outperform
Zimmer Biomet Holdings3.96%$297.92K$18.41B-12.85%
73
Outperform
Campbell Soup3.23%$243.03K$7.69B-38.29%
60
Neutral
Applied Materials3.13%$235.29K$257.72B108.59%
77
Outperform

MVAL Technical Analysis

Technical Analysis Sentiment
Neutral
Last Price
Price Trends
50DMA
38.11
Negative
100DMA
36.62
Positive
200DMA
34.77
Positive
Market Momentum
MACD
-0.04
Positive
RSI
31.89
Neutral
STOCH
8.89
Positive
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For MVAL, the sentiment is Neutral. The current price of undefined is equal to the 20-day moving average (MA) of 38.93, equal to the 50-day MA of 38.11, and equal to the 200-day MA of 34.77, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 31.89 is Neutral, neither overbought nor oversold. The STOCH value of 8.89 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for MVAL.

MVAL Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$7.50M0.50%
70
Neutral
$97.41M0.91%
72
Outperform
$91.03M0.85%
63
Neutral
$80.41M0.50%
73
Outperform
$56.60M0.30%
67
Neutral
$42.58M0.45%
72
Outperform
Performance Comparison
Ticker
Company Name
Price
Change
% Change
MVAL
VanEck Morningstar Wide Moat Value ETF
37.16
5.27
16.53%
BAMV
Brookstone Value Stock ETF
TCV
Towle Value ETF
GMOV
GMO US Value ETF
VUSV
Vanguard Wellington U.S. Value Active ETF
GVLE
Goldman Sachs Value Opportunities ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement